Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Will Lawn is active.

Publication


Featured researches published by Will Lawn.


Journal of Psychopharmacology | 2014

The NBOMe hallucinogenic drug series: Patterns of use, characteristics of users and self-reported effects in a large international sample

Will Lawn; Monica J. Barratt; Martin Williams; Abigail Horne; Adam R. Winstock

The NBOMe compounds are a novel series of hallucinogenic drugs that are potent agonists of the 5-HT2A receptor, have a short history of human consumption and are available to buy online, in most countries. In this study, we sought to investigate the patterns of use, characteristics of users and self-reported effects. A cross-sectional anonymous online survey exploring the patterns of drug use was conducted in 2012 (n = 22,289), including questions about the use of 25B-NBOMe, 25C-NBOMe, and 25I-NBOMe and comparison drugs. We found that 2.6% of respondents (n = 582) reported having ever tried one of the three NBOMe drugs and that at 2.0%, 25I-NBOMe was the most popular (n = 442). Almost all (93.5%) respondents whose last new drug tried was a NBOMe drug, tried it in 2012, and 81.2% of this group administered the drug orally or sublingually/buccally. Subjective effects were similar to comparison serotonergic hallucinogens, though higher ‘negative effects while high’ and greater ‘value for money’ were reported. The most common (41.7%) drug source was via a website. The NBOMe drugs have emerged recently, are frequently bought using the internet and have similar effects to other hallucinogenic drugs; however, they may pose larger risks, due to the limited knowledge about them, their relatively low price and availability via the internet.


Translational Psychiatry | 2015

Rewriting the valuation and salience of alcohol-related stimuli via memory reconsolidation.

Ravi K. Das; Will Lawn; Sunjeev K. Kamboj

The transient period of memory instability that can be triggered when memories are retrieved under certain conditions offers an opportunity to modify the maladaptive memories at the heart of substance use disorders (SUDs). However, very well-learned memories (such as those in excessive drinking and alcohol use disorders) are resistant to destabilisation when retrieved or may not destabilise at all. Memory retrieval and intervention procedures that reliably destabilise and update maladaptive motivational memories may help to improve the long-term treatment of SUDs. In 59 hazardous drinkers, we tested a novel retrieval procedure for destabilising well-learned cue-drinking memory networks that maximises prediction error (PE) via guided expectancy violation during retrieval of these memories. This was compared with a retrieval procedure without PE and no-retrieval controls. We subsequently counterconditioned alcohol cues with disgusting tastes and images in all groups and assessed responding to alcohol stimuli 1 week later. Counterconditioning following PE retrieval produced generalised reductions in oculomotor attentional bias, explicit valuation and outcome expectancies in response to alcohol cues 1 week after intervention, evidence of updating of distributed motivational drinking memory networks. These findings demonstrate that well-learned cue-drinking memories can be destabilised and that learning history need not constrain memory destabilisation if PE is maximised at retrieval. Broad rewriting of diverse aspects of maladaptive memory by counterconditioning is achievable following this procedure. The procedure described may provide a platform for the development of novel memory-modifying interventions for SUDs.


Journal of Substance Use | 2014

Methoxetamine: prevalence of use in the USA and UK and associated urinary problems

Will Lawn; Rohan Borschmann; Angela M. Cottrell; Adam R. Winstock

Abstract Background: Methoxetamine is a novel psychoactive substance and a legal alternative to ketamine in many countries, including parts of the United States. Frequent recreational ketamine use can cause lower urinary tract symptoms, whereas methoxetamine was originally marketed as “bladder friendly”. Aims: (1) To determine changes in prevalence of methoxetamine use between 2011 and 2012 in the USA and UK and (2) to investigate the prevalence of urinary symptoms in group of methoxetamine users, who had also used ketamine at least once in their lifetime. Methods: Cross-sectional, anonymous online surveys exploring patterns of drug use were conducted in late 2011 (n = 15 200) and late 2012 (n = 22 289). Results: Reported lifetime, past 12 months, and last month methoxetamine use significantly increased in the USA between 2011 and 2012; whereas, during the same period, past 12 months and last month methoxetamine use significantly decreased in the UK. Of the methoxetamine users questioned in the 2012 survey, 23.0% (n = 98) reported experiencing urinary symptoms. Prevalence of at least one urinary symptom was related to frequency of methoxetamine use in the last month. Conclusions: Methoxetamine use appeared to increase in the United States and decrease in the UK between 2011 and 2012. Approximately, one-quarter of methoxetamine users questioned reported urinary symptoms; however, previous ketamine use cannot be ruled out as the cause of the symptoms.


Psychopharmacology | 2015

The effects of nicotine dependence and acute abstinence on the processing of drug and non-drug rewards

Will Lawn; Tom P. Freeman; Chandni Hindocha; Claire Mokrysz; Ravi K. Das; Celia J. A. Morgan; H.V. Curran

RationaleDrug addiction may be characterised by a hypersensitivity to drug rewards and a hyposensitivity to non-drug rewards. This imbalance may become further polarised during acute abstinence.Objectives(i) Examine the differences between dependent and occasional smokers in choices for, motivation for and self-reported wanting and liking of cigarette and non-drug rewards. (ii) Examine the effects of 12-h nicotine abstinence on these metrics.MethodsDependent (n = 20) and occasional, non-dependent smokers (n = 20) were tested after ad libitum smoking and ≥12-h of nicotine abstinence. A novel task was developed (Drug, Reward and Motivation–Choice (DReaM-Choice)) in which different rewards (cigarettes, music and chocolate) could be won. In each trial, participants chose between two rewards and then could earn the chosen reward via repeated button-pressing. Participants subsequently ‘consumed’ and rated subjective liking of the rewards they had won.ResultsCompared with occasional smokers, dependent smokers made more choices for (p < 0.001), pressed more for (p = 0.046) and reported more wanting (p = 0.007) and liking (p < 0.001) of cigarettes, and also made fewer choices for chocolate (p = 0.005). There were no differences between the groups on button-pressing for chocolate or music. However, the balance between drug and non-drug reward processing was different between the groups across all metrics. Twelve-hour nicotine abstinence led to more cigarette choices (p < 0.001) and fewer music choices (p = 0.042) in both groups.ConclusionsNicotine dependence was associated with a hypersensitivity to cigarette rewards, but we found little evidence indicating a hyposensitivity to non-drug rewards. Our findings question the moderating influence of dependence on how acute nicotine abstinence affects reward processing.


Journal of Psychopharmacology | 2015

Recreational 3,4-methylenedioxy-N-methylamphetamine (MDMA) or ‘ecstasy’ and self-focused compassion: Preliminary steps in the development of a therapeutic psychopharmacology of contemplative practices

Sunjeev K. Kamboj; Emma J. Kilford; Stephanie Minchin; Abigail Moss; Will Lawn; Ravi K. Das; Caroline J. Falconer; Paul Gilbert; H. Valerie Curran; Tom P. Freeman

3,4-methylenedioxy-N-methylamphetamine (MDMA) produces diverse pro-social effects. Cognitive training methods rooted in Eastern contemplative practices also produce these effects through the development of a compassionate mindset. Given this similarity, we propose that one potential mechanism of action of MDMA in psychotherapy is through enhancing effects on intrapersonal attitudes (i.e. pro-social attitudes towards the self). We provide a preliminary test of this idea. Recreational MDMA (ecstasy) users were tested on two occasions, having consumed or not consumed ecstasy. Self-critical and self-compassionate responses to self-threatening scenarios were assessed before (T1) and after (T2) ecstasy use (or non-use), and then after compassionate imagery (T3). Moderating roles of dispositional self-criticism and avoidant attachment were examined. Separately, compassionate imagery and ecstasy produced similar sociotropic effects, as well as increases in self-compassion and reductions in self-criticism. Higher attachment-related avoidance was associated with additive effects of compassionate imagery and ecstasy on self-compassion. Findings were in line with MDMA’s neuropharmacological profile, its phenomenological effects and its proposed adjunctive use in psychotherapy. However, although conditions were balanced, the experiment was non-blind and MDMA dose/purity was not determined. Controlled studies with pharmaceutically pure MDMA are still needed to test these effects rigorously.


Nicotine & Tobacco Research | 2018

The Acute Effects of a Dopamine D3 Receptor Preferring Agonist on Motivation for Cigarettes in Dependent and Occasional Cigarette Smokers

Will Lawn; Tom P. Freeman; Katie East; Annie Gaule; Elizabeth R. Aston; Michael Bloomfield; Ravi K. Das; Celia J. A. Morgan; H. Valerie Curran

Abstract Background Dopaminergic functioning is thought to play critical roles in both motivation and addiction. There is preliminary evidence that dopamine agonists reduce the motivation for cigarettes in smokers. However, the effects of pramipexole, a dopamine D3 receptor preferring agonist, have not been investigated. The aim of this study was to examine the effects of an acute dose of pramipexole on the motivation to earn cigarettes and nondrug rewards. Methods Twenty dependent and 20 occasional smokers received 0.5 mg pramipexole using a double-blind, placebo-controlled crossover design. Motivation for cigarettes and consummatory nondrug rewards was measured using the DReaM-Choice task, in which participants earned, and later “consumed,” cigarettes, music, and chocolate. Demand for cigarettes was measured using the Cigarette Purchase Task (CPT). Self-reported craving, withdrawal, and drug effects were also recorded. Results Dependent smokers chose (p < .001) and button-pressed for (p < .001) cigarettes more, and chose chocolate less (p < .001), than occasional smokers. Pramipexole did not affect the number of choices for or amount of button-pressing for any reward including cigarettes, which was supported by a Bayesian analysis. The dependent smokers had greater demand for cigarettes than occasional smokers across all CPT outcomes (ps < .021), apart from elasticity. Pramipexole did not affect demand for cigarettes, and this was supported by Bayesian analyses. Pramipexole produced greater subjective “feel drug” and “dislike drug” effects than placebo. Conclusions Dependent and occasional cigarette smokers differed in their motivation for cigarettes but not for the nondrug rewards. Pramipexole did not acutely alter motivation for cigarettes. These findings question the role of dopamine D3 receptors in cigarette-seeking behavior in dependent and occasional smokers. Implications This study adds to the growing literature about cigarette versus nondrug reward processing in nicotine dependence and the role of dopamine in cigarette-seeking behavior. Our results suggest nicotine dependence is associated with a hypersensitivity to cigarette rewards but not a hyposensitivity to nondrug rewards. Furthermore, our results question the importance of dopamine D3 receptors in motivational processing of cigarettes in occasional and dependent smokers.


The International Journal of Neuropsychopharmacology | 2018

Cannabis dampens the effects of music in brain regions sensitive to reward and emotion

Tom P. Freeman; R.A. Pope; Matthew B. Wall; Ja Bisby; M. Luijten; Chandni Hindocha; Claire Mokrysz; Will Lawn; Abigail Moss; Michael Bloomfield; Celia J. A. Morgan; David J. Nutt; H.V. Curran

Abstract Background Despite the current shift towards permissive cannabis policies, few studies have investigated the pleasurable effects users seek. Here, we investigate the effects of cannabis on listening to music, a rewarding activity that frequently occurs in the context of recreational cannabis use. We additionally tested how these effects are influenced by cannabidiol, which may offset cannabis-related harms. Methods Across 3 sessions, 16 cannabis users inhaled cannabis with cannabidiol, cannabis without cannabidiol, and placebo. We compared their response to music relative to control excerpts of scrambled sound during functional Magnetic Resonance Imaging within regions identified in a meta-analysis of music-evoked reward and emotion. All results were False Discovery Rate corrected (P<.05). Results Compared with placebo, cannabis without cannabidiol dampened response to music in bilateral auditory cortex (right: P=.005, left: P=.008), right hippocampus/parahippocampal gyrus (P=.025), right amygdala (P=.025), and right ventral striatum (P=.033). Across all sessions, the effects of music in this ventral striatal region correlated with pleasure ratings (P=.002) and increased functional connectivity with auditory cortex (right: P< .001, left: P< .001), supporting its involvement in music reward. Functional connectivity between right ventral striatum and auditory cortex was increased by cannabidiol (right: P=.003, left: P=.030), and cannabis with cannabidiol did not differ from placebo on any functional Magnetic Resonance Imaging measures. Both types of cannabis increased ratings of wanting to listen to music (P<.002) and enhanced sound perception (P<.001). Conclusions Cannabis dampens the effects of music in brain regions sensitive to reward and emotion. These effects were offset by a key cannabis constituent, cannabidol.


Neuropharmacology | 2018

Ketamine for the treatment of addiction: Evidence and potential mechanisms

I. Ivan Ezquerra-Romano; Will Lawn; E. Krupitsky; Celia J. A. Morgan

&NA; Ketamine is a dissociative anaesthetic drug which acts on the central nervous system chiefly through antagonism of the n‐methyl‐d‐aspartate (NMDA) receptor. Recently, ketamine has attracted attention as a rapid‐acting anti‐depressant but other studies have also reported its efficacy in reducing problematic alcohol and drug use. This review explores the preclinical and clinical research into ketamines ability to treat addiction. Despite methodological limitations and the relative infancy of the field, results thus far are promising. Ketamine has been shown to effectively prolong abstinence from alcohol and heroin in detoxified alcoholics and heroin dependent individuals, respectively. Moreover, ketamine reduced craving for and self‐administration of cocaine in non‐treatment seeking cocaine users. However, further randomised controlled trials are urgently needed to confirm ketamines efficacy. Possible mechanisms by which ketamine may work within addiction include: enhancement of neuroplasticity and neurogenesis, disruption of relevant functional neural networks, treating depressive symptoms, blocking reconsolidation of drug‐related memories, provoking mystical experiences and enhancing psychological therapy efficacy. Identifying the mechanisms by which ketamine exerts its therapeutic effects in addiction, from the many possible candidates, is crucial for advancing this treatment and may have broader implications understanding other psychedelic therapies. In conclusion, ketamine shows great promise as a treatment for various addictions, but well‐controlled research is urgently needed. This article is part of the Special Issue entitled ‘Psychedelics: New Doors, Altered Perceptions’. HighlightsPreliminary evidence suggests that ketamine may be effective in addiction.Potential interacting mechanisms are enhancing neurogenesis and psychological therapies.Ketamine may reduce depressive symptoms in a risky window for addiction relapse.


Psychopharmacology | 2017

Individual and combined effects of cannabis and tobacco on drug reward processing in non-dependent users

Chandni Hindocha; Will Lawn; Tom P. Freeman; H. Valerie Curran

RationaleCannabis and tobacco are often smoked simultaneously in joints, and this practice may increase the risks of developing tobacco and/or cannabis use disorders. Currently, there is no human experimental research on how these drugs interact on addiction-related measures.ObjectivesThis study aimed to investigate how cannabis and tobacco, each alone and combined together in joints, affected individuals’ demand for cannabis puffs and cigarettes, explicit liking of drug and non-drug-related stimuli and craving.MethodA double-blind, 2 (active cannabis, placebo cannabis) × 2 (active tobacco, placebo tobacco) crossover design was used with 24 non-dependent cannabis and tobacco smokers. They completed a pleasantness rating task (PRT), a marijuana purchase task (MPT) and a cigarette purchase task (CPT) alongside measures of craving pre- and post-drug administration.ResultsRelative to placebo cannabis, active cannabis reduced liking of cannabis-associated stimuli and increased response time to all stimuli except cigarette-related stimuli. Relative to placebo cannabis, active cannabis decreased demand for cannabis puffs (trends for breakpoint and elasticity) and cigarettes (breakpoint, Pmax, Omax) on several characteristics of the purchase tasks. We found no evidence that active tobacco, both alone or combined with cannabis, had an effect on liking, demand or craving.ConclusionsAcutely, cannabis reduced liking of cannabis-related stimuli and demand for cannabis itself. Acute cannabis also reduced demand for cigarettes on the CPT. Acute tobacco administration did not affect demand or pleasantness ratings for cigarettes themselves or cannabis. In non-dependent cannabis and tobacco co-users, tobacco did not influence the rewarding effects of cannabis.


Frontiers in Psychology | 2016

A Moderate Dose of Alcohol Does Not Influence Experience of Social Ostracism in Hazardous Drinkers

Joseph Buckingham; Abigail Moss; Krisztina Gyure; Neil Ralph; Chandni Hindocha; Will Lawn; H. Valerie Curran; Tom P. Freeman

Anecdotal and correlational evidence suggests a relationship between social ostracism and alcohol dependence. Furthermore, a recent fMRI investigation found differences in the neural correlates associated with ostracism in people with alcohol dependence compared to healthy controls. We predicted that acutely administered alcohol would reduce the negative effects of social ostracism. Alcohol (0.4 g/kg) or matched placebo was administered to a sample of 32 hazardous drinkers over two sessions in a randomized, double-blind, cross-over design. In each session, participants were exposed to an ostracism event via the computerized ball passing game, “Cyberball.” In order to quantify the effects of ostracism, the fundamental needs questionnaire was completed twice on each testing session; immediately after (i) social inclusion and (ii) social exclusion. Ostracism caused robust changes to scores on the fundamental needs questionnaire, in line with previous literature. Alcohol administration did not influence the effects of simulated social ostracism, which was supported by a Bayesian analysis. Exploratory analyses revealed a negative relationship between age and ostracism induced fundamental needs threat across both sessions. In conclusion, a moderate dose of alcohol did not influence experience of simulated social ostracism in hazardous drinkers. Further research is needed to establish the effects of alcohol administration on social ostracism using different doses and populations of alcohol users.

Collaboration


Dive into the Will Lawn's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Tom P. Freeman

University College London

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ravi K. Das

University College London

View shared research outputs
Top Co-Authors

Avatar

Abigail Moss

University College London

View shared research outputs
Top Co-Authors

Avatar

H.V. Curran

University College London

View shared research outputs
Top Co-Authors

Avatar

Claire Mokrysz

University College London

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

R.A. Pope

University College London

View shared research outputs
Researchain Logo
Decentralizing Knowledge